Back to Browse Journals » Vascular Health and Risk Management » Volume 6

An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog

Authors Katarina Raslova

Published 24 May 2010 Volume 2010:6 Pages 399—410

DOI http://dx.doi.org/10.2147/VHRM.S10397

Review by Single-blind

Peer reviewer comments 6

Katarina Raslova

Metabolic Center Ltd and Slovak Medical University, Bratislava, Slovak Republic

Abstract: Basal insulin analogs are used to minimize unpredictable processes of NPH insulin. Modification of the human insulin molecule results in a slower distribution to peripheral target tissues, a longer duration of action with stable concentrations and thus a lower rate of hypoglycemia. Insulin detemir is a basal insulin analog that provides effective therapeutic options for patients with type 1 and type 2 diabetes. For glycemic control, no significant differences were found in HbA1c levels compared with NPH and insulin glargine. It is comparable with insulin glargine in significantly reducing rates of all types of hypoglycemia. Clinical studies have demonstrated that detemir is responsible for significantly lower within-subject variability and no or less weight gain than NPH insulin and glargine. Recent pharmacodynamic studies have shown that detemir can be used once daily in many patients with diabetes. Together with patient-friendly injection devices and dose adjustments, it provides a treatment option with the potential to lower the key barriers of adherence to insulin therapy in type 2 diabetes. Recent guidelines for treatment of type 2 diabetes suggest starting intensive therapy of hyperglycemia at an early stage of diabetes and recommend therapeutic options that provide the possibility of reaching HbA1c goals individually, with a low risk of hypoglycemia or other adverse effects of treatment. The properties of insulin detemir match these requirements.

Keywords: insulin analog, insulin detemir, diabetes mellitus, hypoglycemia, within-subject variability

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Biocompatibility of magnetic Fe3O4 nanoparticles and their cytotoxic effect on MCF-7 cells

Chen DZ, Tang QS, Li XD, Zhou XJ, Zang J, Xue WQ, Xiang JY, Guo CQ

International Journal of Nanomedicine 2012, 7:4973-4982

Published Date: 14 September 2012

Solid lipid nanoparticle suspension enhanced the therapeutic efficacy of praziquantel against tapeworm

Xie S, Pan B, Shi B, Zhang Z, Zhang X, Wang M, Zhou W

International Journal of Nanomedicine 2011, 6:2367-2374

Published Date: 18 October 2011

Erratum

Xiao N, Shi S, Zhuang H

Hepatic Medicine: Evidence and Research 2011, 3:19-20

Published Date: 18 March 2011

Argatroban in the management of heparin-induced thrombocytopenia

Luciano Babuin, Vittorio Pengo

Vascular Health and Risk Management 2010, 6:813-819

Published Date: 1 September 2010

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment

Curtis Triplitt, Eugenio Cersosimo, Ralph A DeFronzo

Vascular Health and Risk Management 2010, 6:671-690

Published Date: 5 August 2010

Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection

Domenico Galzerano, Cristina Capogrosso, Sara Di Michele, et al

Vascular Health and Risk Management 2010, 6:479-494

Published Date: 22 June 2010

Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update

Maurizio Destro, Francesca Cagnoni, Antonio D’Ospina, et al

Vascular Health and Risk Management 2010, 6:253-260

Published Date: 14 April 2010

Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole

David J Muzina

Neuropsychiatric Disease and Treatment 2009, 5:279-288

Published Date: 19 May 2009

Bisoprolol in the treatment of chronic heart failure

Pascal de Groote, Pierre-Vladimir Ennezat, Fréderic Mouquet

Vascular Health and Risk Management 2007, 3:431-439

Published Date: 15 September 2007